S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Criteria the registry did not label

• DISEASE CHARACTERISTICS:
• Histologically confirmed previously untreated bulky stage II or stage III or IV follicular non-Hodgkin's lymphoma
  • Grade I-III disease
• Cluster of differentiation antigen 20 (CD20) antigen positive
• Fewer than 5,000/mm\^3 circulating lymphoid cells on a white blood cell (WBC) differential count
• Bidimensionally measurable disease
• Bone marrow aspiration and biopsy within the past 42 days
• No clinical evidence of central nervous system (CNS) involvement by lymphoma
  • PATIENT CHARACTERISTICS:
  • Age:
• 18 and over
  • Performance status:
• Zubrod 0-2
  • Life expectancy:
• Not specified
  • Hematopoietic:
• See Disease Characteristics
• Granulocyte count greater than 1,500/mm\^3
• Platelet count greater than 100,000/mm\^3
  • Hepatic:
• Not specified
  • Renal:
• Not specified
  • Cardiovascular:
• No impaired cardiac status, including:
  • Severe coronary artery disease
  • Cardiomyopathy
  • Congestive heart failure
  • Serious arrhythmia
• Ejection fraction at least lower limit of normal by Multi Gated Acquisition Scan (MUGA) or 2-D echocardiogram for questionable cardiac history
  • Other:
• No hypersensitivity to iodine
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 6 months after study participation
• HIV negative
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy:
• No prior monoclonal antibodies for cancer
  • Chemotherapy:
• No prior chemotherapy for lymphoma
  • Prior prednisone for non-lymphoma related illnesses allowed
  • Endocrine therapy:
• Not specified
  • Radiotherapy:
• No prior radiotherapy for lymphoma
  • Surgery:
• See Disease Characteristics